Not Signed In -
Exelon |
rivastigmine tartrate |
Clinical Trial: Electrophysiologic Measures of Treatment Response in Alzheimer Disease
This study has been completed.
|
Purpose
The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Alzheimer Disease | Drug: Aricept Drug: Exelon Drug: Nicoderm Patch | Phase IV |
MedlinePlus related topics: Alzheimer's Caregivers; Alzheimer's Disease
Genetics Home Reference related topics: Alzheimer disease
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study
Official Title: Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease
Study start: October 1998; Study completion: September 2001
Eligibility
Ages Eligible for Study: 55 Years - 85 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Location Information
California
Department of Veterans Affairs, San Diego, California, 92161, United States
Vincente Iragui, M.D., Ph.D
Shuanna Morris, Ph.D.
More Information
Record last reviewed: December 2004
Last Updated: December 30, 2004
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018278
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Exelon Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
